title: Acute myeloid leukemia, version 2.2013.
abstract: These NCCN Guidelines Insights summarize several key updates to the NCCN Guidelines for Acute Myeloid Leukemia and discuss the clinical evidence that support the recommendations. The updates described in this article focus on the acute promyelocytic leukemia (APL) section, featuring recommendations for additional induction/consolidation regimens in patients with low- or intermediate-risk APL, and providing guidance on maintenance strategies for APL.
authors.affiliation: From 1City of Hope Comprehensive Cancer Center; 2Memorial Sloan-Kettering Cancer Center; 3Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; 4Robert H. Lurie Comprehensive Cancer Center of Northwestern University; 5Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; 6Stanford Cancer Institute; 7Massachusetts General Hospital Cancer Center; 8University of Alabama at Birmingham Comprehensive Cancer Center; 9UCSF Helen Diller Family Comprehensive Cancer Center; 10Moffitt Cancer Center; 11UNMC Eppley Cancer Center at The Nebraska Medical Center; 12The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; 13St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; 14Fox Chase Cancer Center; 15Duke Cancer Institute; 16The University of Texas MD Anderson Cancer Center; 17Huntsman Cancer Institute at the University of Utah; 18The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; 19Dana-Farber Cancer Institute; 20Vanderbilt-Ingram Cancer Center; 21Roswell Park Cancer Institute; and 22National Comprehensive Cancer Network.
authors.forename: Margaret R
authors.initials: MR
authors.lastname: O'Donnell
authors.forename: Martin S
authors.initials: MS
authors.lastname: Tallman
authors.forename: Camille N
authors.initials: CN
authors.lastname: Abboud
authors.forename: Jessica K
authors.initials: JK
authors.lastname: Altman
authors.forename: Frederick R
authors.initials: FR
authors.lastname: Appelbaum
authors.forename: Daniel A
authors.initials: DA
authors.lastname: Arber
authors.forename: Eyal
authors.initials: E
authors.lastname: Attar
authors.forename: Uma
authors.initials: U
authors.lastname: Borate
authors.forename: Steven E
authors.initials: SE
authors.lastname: Coutre
authors.forename: Lloyd E
authors.initials: LE
authors.lastname: Damon
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Lancet
authors.forename: Lori J
authors.initials: LJ
authors.lastname: Maness
authors.forename: Guido
authors.initials: G
authors.lastname: Marcucci
authors.forename: Michael G
authors.initials: MG
authors.lastname: Martin
authors.forename: Michael M
authors.initials: MM
authors.lastname: Millenson
authors.forename: Joseph O
authors.initials: JO
authors.lastname: Moore
authors.forename: Farhad
authors.initials: F
authors.lastname: Ravandi
authors.forename: Paul J
authors.initials: PJ
authors.lastname: Shami
authors.forename: B Douglas
authors.initials: BD
authors.lastname: Smith
authors.forename: Richard M
authors.initials: RM
authors.lastname: Stone
authors.forename: Stephen A
authors.initials: SA
authors.lastname: Strickland
authors.forename: Eunice S
authors.initials: ES
authors.lastname: Wang
authors.forename: Kristina M
authors.initials: KM
authors.lastname: Gregory
authors.forename: Maoko
authors.initials: M
authors.lastname: Naganuma
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy*
references.citation: Blood. 2002 Dec 15;100(13):4298-302
references.pmid: 12393590
references.citation: N Engl J Med. 2013 Jul 11;369(2):111-21
references.pmid: 23841729
references.citation: Blood. 1997 May 1;89(9):3354-60
references.pmid: 9129042
references.citation: Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5328-35
references.pmid: 15044693
references.citation: Blood. 2011 Aug 4;118(5):1248-54
references.pmid: 21653939
references.citation: Blood. 2011 May 5;117(18):4716-25
references.pmid: 21385856
references.citation: Blood. 1999 Aug 15;94(4):1192-200
references.pmid: 10438706
references.citation: Blood. 2007 Jul 1;110(1):59-66
references.pmid: 17374742
references.citation: Blood. 2010 Mar 4;115(9):1690-6
references.pmid: 20018913
references.citation: Hematology Am Soc Hematol Educ Program. 2008;:391-9
references.pmid: 19074116
references.citation: Blood. 2010 Jun 24;115(25):5137-46
references.pmid: 20393132
references.citation: CA Cancer J Clin. 2013 Jan;63(1):11-30
references.pmid: 23335087
references.citation: Expert Rev Anticancer Ther. 2011 Sep;11(9):1317-9
references.pmid: 21929304
references.citation: Blood. 2008 Feb 1;111(3):1078-84
references.pmid: 17975017
references.citation: Blood. 2010 Oct 28;116(17):3171-9
references.pmid: 20644121
references.citation: Blood. 2010 Nov 11;116(19):3751-7
references.pmid: 20705755
references.citation: J Clin Oncol. 2009 Feb 1;27(4):504-10
references.pmid: 19075265
references.citation: Blood. 2006 May 1;107(9):3469-73
references.pmid: 16373661